Biogen (BIIB) PT Raised to $408 at Cowen
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $197.19 -1.26%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.
Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norwegian Cruise (NCLH) PT Raised to $24 at TD Cowen
- Berenberg Starts Natwest Group PLC (NWG:LN) (NWG) at Buy
- Berenberg Starts Barclays Plc (BARC:LN) (BCS) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
